Jazz Pharmaceuticals Public's Earnings Beat Last Year's by 51%

Jazz Pharmaceuticals Public (Nasdaq: JAZZ  ) reported earnings on May 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Jazz Pharmaceuticals Public beat expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share grew significantly. GAAP earnings per share expanded significantly.

Margins contracted across the board.

Revenue details
Jazz Pharmaceuticals Public chalked up revenue of $196.2 million. The 10 analysts polled by S&P Capital IQ anticipated revenue of $190.9 million on the same basis. GAAP reported sales were 81% higher than the prior-year quarter's $108.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.37. The 13 earnings estimates compiled by S&P Capital IQ anticipated $1.35 per share. Non-GAAP EPS of $1.37 for Q1 were 51% higher than the prior-year quarter's $0.91 per share. GAAP EPS of $0.71 for Q1 were 48% higher than the prior-year quarter's $0.48 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 86.1%, 620 basis points worse than the prior-year quarter. Operating margin was 34.7%, 370 basis points worse than the prior-year quarter. Net margin was 22.1%, 340 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $204.5 million. On the bottom line, the average EPS estimate is $1.48.

Next year's average estimate for revenue is $830.0 million. The average EPS estimate is $5.96.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 233 members out of 296 rating the stock outperform, and 63 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Jazz Pharmaceuticals Public a green thumbs-up, and 15 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $71.36.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2418484, ~/Articles/ArticleHandler.aspx, 7/29/2014 3:41:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement